Subscribe to our Newsletters !!
Cell therapy is a medical breakthrough in addressi
Chromium, a transition metal with profound pharmac
Few names in the medical history have had a profou
We are pleased to announce that we have recently e
Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and her
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of Mi
Although both biologics and biosimilars are significant drug classes utilized in healthcare, they differ in terms of their properties, approval processes, and price points.
Here’s a breakdown of their similarities and differences:
In conclusion, biosimilars are created as extremely similar replacements that are presented after the patent protection of the reference biologic has expired. Biologics, on the other hand, are the original, complicated drugs derived from living creatures and go through significant regulatory processes. Biosimilars offer market competition, potentially driving down prices and expanding access to these crucial treatments. Nevertheless, the procedure for regulatory approval guarantees that biosimilars are secure and efficient for patient usage.